Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

Share Price is delayed by 15 minutes
Get Live Data
13,354.00    0.00 (0.00%)
Bid:
12,900.00
Ask:
14,000.00
Spread: 1,100.00 (8.527%)
Market Cap: £207.10b
AZN Live PriceLast checked at - London Stock Exchange

Intraday Astrazeneca Share Chart

Form 8.5 (EPT/RI)

21 May 2014 11:52

RNS Number : 6959H
GoldmanSachs International
21 May 2014
 



 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

(GS) GOLDMAN SACHS INTERNATIONAL

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

ASTRAZENECA PLC

(c) Name of the party to the offer with which exempt principal trader is connected:

ASTRAZENECA PLC

(d) Date dealing undertaken:

20 May 2014

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

YES - disclosed previously for PFIZER INC

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

USD 0.25 ordinary

Purchases

1,872,0075,88215,000

43.0850 GBP478.3000 SEK72.2700 USD

41.8850 GBP468.0000 SEK72.2700 USD

USD 0.25 ordinary

Sales

1,431,1785,882

43.0850 GBP474.4000 SEK

41.9150 GBP469.0000 SEK

ADR

Purchases

50,000

72.4131 USD

72.3189 USD

ADR

Sales

50,000

72.3660 USD

72.3660 USD

 

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

USD 0.25 ordinary

CFD

Opening a short position

1,000

42.0450 GBP

USD 0.25 ordinary

CFD

Opening a long position

15,000

42.1389 GBP

USD 0.25 ordinary

CFD

Opening a short position

380

42.1500 GBP

USD 0.25 ordinary

CFD

Opening a short position

37,860

42.1576 GBP

USD 0.25 ordinary

CFD

Opening a short position

5,546

42.2479 GBP

USD 0.25 ordinary

CFD

Opening a short position

146,078

42.2479 GBP

USD 0.25 ordinary

CFD

Opening a long position

6,500

42.2695 GBP

USD 0.25 ordinary

CFD

Opening a long position

18,400

42.3325 GBP

USD 0.25 ordinary

CFD

Reducing a short position

7,180

42.6685 GBP

USD 0.25 ordinary

CFD

Opening a short position

125

42.6802 GBP

USD 0.25 ordinary

CFD

Reducing a short position

500

42.7204 GBP

USD 0.25 ordinary

CFD

Reducing a short position

12,500

42.8083 GBP

USD 0.25 ordinary

CFD

Opening a short position

12,500

42.8349 GBP

USD 0.25 ordinary

CFD

Opening a short position

7,180

42.8445 GBP

USD 0.25 ordinary

CFD

Reducing a short position

2,000

42.8550 GBP

USD 0.25 ordinary

CFD

Reducing a short position

14,394

42.8554 GBP

USD 0.25 ordinary

CFD

Reducing a short position

6,780

42.8554 GBP

USD 0.25 ordinary

CFD

Reducing a short position

3,826

42.8554 GBP

USD 0.25 ordinary

CFD

Reducing a long position

3,984

42.9066 GBP

USD 0.25 ordinary

CFD

Opening a short position

50,000

43.0461 GBP

USD 0.25 ordinary

CFD

Opening a long position

10,000

43.0850 GBP

USD 0.25 ordinary

CFD

Reducing a short position

380

43.0850 GBP

USD 0.25 ordinary

CFD

Opening a short position

15,000

72.2700 USD

 

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

ADR

Call Option / (1.00 : 100.00)

Purchasing

750 (75,000)

77.5000 USD

AMERICAN

19/07/2014

2.4200 USD

ADR

Call Option / (1.00 : 100.00)

Selling

750 (75,000)

72.5000 USD

AMERICAN

19/07/2014

4.1200 USD

ADR

Put Option / (1.00 : 100.00)

Purchasing

39 (3,900)

60.0000 USD

AMERICAN

18/10/2014

1.0500 USD

ADR

Put Option / (1.00 : 100.00)

Purchasing

11 (1,100)

60.0000 USD

AMERICAN

18/10/2014

1.0500 USD

ADR

Put Option / (1.00 : 100.00)

Selling

11 (1,100)

60.0000 USD

AMERICAN

18/10/2014

1.0500 USD

ADR

Put Option / (1.00 : 100.00)

Selling

39 (3,900)

60.0000 USD

AMERICAN

18/10/2014

1.0500 USD

USD 0.25 ordinary

Call Option / (1.00 : 1,000.00)

Selling

300 (300,000)

46.0000 GBP

AMERICAN

19/09/2014

1.8700 GBP

USD 0.25 ordinary

Call Option / (1.00 : 1,000.00)

Selling

300 (300,000)

46.0000 GBP

AMERICAN

19/09/2014

1.8700 GBP

USD 0.25 ordinary

Call Option / (1.00 : 1,000.00)

Selling

300 (300,000)

46.0000 GBP

AMERICAN

19/09/2014

1.8700 GBP

USD 0.25 ordinary

Put Option / (1.00 : 1,000.00)

Purchasing

300 (300,000)

40.0000 GBP

AMERICAN

19/09/2014

2.0000 GBP

USD 0.25 ordinary

Put Option / (1.00 : 1,000.00)

Purchasing

300 (300,000)

40.0000 GBP

AMERICAN

19/09/2014

2.0000 GBP

USD 0.25 ordinary

Put Option / (1.00 : 1,000.00)

Purchasing

300 (300,000)

40.0000 GBP

AMERICAN

19/09/2014

2.0000 GBP

 

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

NONE

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

NONE

 

 

 

Date of disclosure:

21 May 2014

Contact name:

Aadithya Rao and Yiannis Bardis

Telephone number:

+44(20) 7051 9046 / +44(20) 7774 7107

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERBGGDUBUDBGSB
Date   Source Headline
1st Nov 20183:00 pmRNSTotal Voting Rights
31st Oct 20189:45 amRNSAdditional financial information-Grünenthal deal
30th Oct 20187:00 amRNSGrünenthal Agreement for rights to Nexium, Vimovo
23rd Oct 20187:00 amRNSAstraZeneca Extends Innate Pharma Collaboration
22nd Oct 20187:00 amRNSLynparza shows 70% reduction in PFS ovarian cancer
19th Oct 20181:09 pmRNSCHMP positive opinion Bevespi Aerosphere
16th Oct 20187:00 amRNSFDA Orphan Drug for Lynparza in pancreatic cancer
1st Oct 20183:00 pmRNSTotal Voting Rights
1st Oct 20187:00 amRNSAtacand Agreement with Cheplapharm Completed
28th Sep 20184:00 pmRNSPrevious Announcement Regarding Appointment Of NED
25th Sep 20181:15 pmRNSOverall survival data for Imfinzi: Stage III NSCLC
24th Sep 20184:10 pmRNSEMA approves AZ's Imfinzi for Stage III NSCLC
24th Sep 20187:00 amRNSFarxiga gets positive result in DECLARE-TIMI 58
14th Sep 20187:00 amRNSFDA approves AZ's Lumoxiti in hairy cell leukaemia
7th Sep 20187:00 amRNSTezepelumab FDA Breakthrough Therapy Designation
6th Sep 20187:00 amRNSDirectorate Change
3rd Sep 20183:00 pmRNSTotal Voting Rights
31st Aug 20187:00 amRNSAstraZeneca Update on Anifrolumab in SLE
30th Aug 20187:00 amRNSEC approves Bydureon BCise device for T2 diabetes
23rd Aug 20187:00 amRNSAstraZeneca PIIIb trial update for Bevespi in COPD
21st Aug 20187:00 amRNSAZ's Tagrisso approved in Japan for 1st-line NSCLC
15th Aug 20187:00 amRNSAstraZeneca prices a $3bn bond issue
3rd Aug 20187:00 amRNSEMA grants OD for selumetinib in NF1
1st Aug 20183:00 pmRNSTotal Voting Rights
27th Jul 20182:00 pmRNSCHMP recommends Imfinzi for Stage III nsclc
26th Jul 20187:00 amRNSAZN: H1 2018 Results
24th Jul 20187:00 amRNSAtacand to be divested to Cheplapharm in Europe
18th Jul 20184:11 pmRNSHolding(s) in Company
18th Jul 201812:00 pmRNSHolding(s) in Company
2nd Jul 20183:00 pmRNSTotal Voting Rights
2nd Jul 20187:00 amRNSLynparza approved in Japan for BRCAm breast cancer
2nd Jul 20187:00 amRNSImfinzi approved in Japan for Stage III nsclc
29th Jun 20183:00 pmRNSBydureon receives positive CHMP opinion for BCise
28th Jun 20181:30 pmRNSAZ and Luye Pharma complete agreement for Seroquel
27th Jun 20187:00 amRNSLynparza: significant PFS 1st-line ovarian cancer
26th Jun 20187:00 amRNSBoard Committee Changes
22nd Jun 20187:00 amRNSPublication of a Prospectus
12th Jun 20187:00 amRNSUpdate: lanabecestat Phase III Alzheimer's trials
8th Jun 20185:30 pmRNSEU APPROVES TAGRISSO FOR 1ST-LINE NSCLC
8th Jun 20187:00 amRNSDirector Declaration
1st Jun 20183:00 pmRNSBlock listing Interim Review
1st Jun 20183:00 pmRNSTotal Voting Rights
1st Jun 201811:00 amRNSDirector Declaration
30th May 20187:00 amRNSUpdate on TERRANOVA PIII trial for Fasenra in COPD
25th May 20187:00 amRNSAZ's Imfinzi: significant OS in Stage III nsclc
21st May 20187:00 amRNSAZ regulatory submission in Japan for Forxiga
21st May 20187:00 amRNSUS FDA approves Lokelma for adult hyperkalaemia
18th May 20185:30 pmRNSResult of AGM
18th May 20187:00 amRNSAZN: Q1 2018 Results
11th May 20187:00 amRNSAstraZeneca update on Fasenra PIII trial in COPD

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.